News and Press Releases

New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma

January 9, 2025 – Sanofi.com

Enable Injections Announces Agreement with Sobi to Develop and Distribute Aspaveli in Combination with enFuse in Sobi Territories

September 12, 2024 – Globe Newswire

Enable Injections Names Matthew Huddleston as Chief Commercial Officer

May 22, 2024 – Globe Newswire

Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse for Advanced Parkinson’s Disease

May 15, 2024 – Globe Newswire

Enable Injections Expands Strategic Partnership with Roche

May 7, 2024 – Globe Newswire

Fierce Medtech Names Enable Injections a “Fierce 15” Company of 2023

March 5, 2024 – PR Newswire

Enable Injections Announces Plans to Expand Manufacturing Facilities and Corporate Headquarters

February 14, 2024 – PR Newswire